Bruker is a performace leader in preclinical imaging instrumentation. Bruker offers nine imaging modalities: PET, SPECT, CT, MRI, MPI, fluorescence, luminiscence, radioisotipic imaging and X-ray.
Discover
Related topics
Advance your Spatial Biology, customize your panel design with RareCyte Orion reagents
Jan 23, 2023
Orion system, the highly multiplexed fluorescent imaging system, in combination with dedicated reagents, empower...
Extensive assessment of Cytokine production on the NovoCyte Advanteon flow cytometer
Jan 13, 2023
Cytokines are small molecules essential for immune cell response to activation by pathogens, autoimmunity, or...
New installation of Cytek Aurora in Slovenia
Jan 11, 2023
2nd spectral flowcytometer Aurora from Cytek was installed at National Institute of Biology in Slovenia
Microfluidic cell sorter sample preparation for genomic assays
Dec 16, 2022
Single-cell RNA-Sequencing has led to many novel discoveries such as the detection of rare cell populations, microbial...
Dec 1, 2022
Cytek Cloud is the new digital ecosystem that supports full spectrum flow cytometry research from panel design to data...
See More, Sort More with Cytek Full Spectrum Systems
Nov 28, 2022
Still wondering whether to join the shift to full spectrum cytometry? Easily transfer assays from your Cytek Northern...
Demonstrate the value of RareCyte Orion system via web-based Minerva viewer
Nov 25, 2022
The HTA CRC Atlas X dataset contains images and other data being used for construction of an atlas of human colorectal...
Practical aspects of an imaging study: live in vivo scanning
Nov 11, 2022
In this webinar, MOLECUBES will present a live in vivo demonstration, showing the entire workflow from animal...
Download the newest AVATAR data presented at CAR-TCR
Oct 21, 2022
Xcell Bio CSO, James Lim, presented new data showcasing improved potency of AVATAR-expanded CAR T cells and highlighted...
RareCyte Orion system advances Multi-modal digital pathology for colorectal cancer diagnosis
Oct 19, 2022
Precision medicine is critically dependent on better methods for diagnosing and staging disease and predicting drug...
Mar 6, 2017
Pheochromocytomas (PHEOs) and extra-adrenal paragangliomas (PGLs) are rare adrenaline-producing tumors. The two tumor types are closely related and are distinguished primarily by their location: pheochromocytomas occur in the center of the adrenal glands while extra-adrenal paragangliomas originate in the paraganglia of the sympathetic nervous system (most commonly in the abdomen). Extra-adrenal paragangliomas are less common, but more likely to be malignant, than pheochromocytomas.
Diagnosis of metastatic PHEOs/PGLs is difficult and tends to rely on identification of adrenaline/noradrenaline production in areas where adrenaline/noradrenaline is not normally produced. Furthermore, such metastases are notoriously difficult to treat. A variety of chemotherapy combinations and radiotherapy are used as palliative treatment, but complete remission is rare.
Consequently, the mouse pheochromocytoma mCherry tumor allograft model was developed, which is functionally similar to human PHEO/PGLs. This mouse model has recently been used to assess the value of the [177Lu]Lu-DOTA-(Tyr3)octreotate (DOTATATE), a labeled somatostatin receptor analog, as a targeted therapy for metastatic PHEO/PGLs in man. And this study confirms that the mCherry model is a uniquely powerful tool for evaluating therapeutic or diagnostic agents that specifically target the somatostatin-2 receptor.
Related technologies: Fluorescence, luminescence, X-ray, radiographic imaging
Brand profile
Bruker is a performace leader in preclinical imaging instrumentation. Bruker offers nine imaging modalities: PET, SPECT, CT, MRI, MPI, fluorescence, luminiscence, radioisotipic imaging and X-ray.
More info at:
www.bruker.com/